Tofacitinib and budesonide treatment affect stemness and chemokine release in IBD patient-derived colonoids
Abstract Restoration of the intestinal epithelial barrier is crucial for achieving mucosal healing, the therapeutic goal for inflammatory bowel disease (IBD). During homeostasis, epithelial renewal is maintained by crypt stem cells and progenitors that cease to divide as they differentiate into matu...
Saved in:
Main Authors: | Arun Sridhar, Ingunn Bakke, Shreya Gopalakrishnan, Nimo Mukhtar Mohamud Osoble, Emilie Prytz Hammarqvist, Henrik P. Sahlin Pettersen, Arne Kristian Sandvik, Ann Elisabet Østvik, Marianne Doré Hansen, Torunn Bruland |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-86314-2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Budesonide in the Management of Patients with Crohn’s Disease
by: ABR Thomson, et al.
Published: (1997-01-01) -
Esophageal Crohn's Disease Treated “Topically” with Swallowed Aerosolized Budesonide
by: Petros Zezos, et al.
Published: (2010-01-01) -
Budesonide in treatment of alcohol-induced severe hepatitis: results of randomized trial
by: I. I. Komkova, et al.
Published: (2013-09-01) -
IBD: Progress in Pathogenesis
by: Claudio Fiocchi, et al.
Published: (1993-01-01) -
The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course
by: Jessica Mwinyi, et al.
Published: (2012-01-01)